Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine
about
Epigenetic therapy in gastrointestinal cancer: the right combinationEmerging therapeutic targets in esophageal adenocarcinomaHistone modifiers and marks define heterogeneous groups of colorectal carcinomas and affect responses to HDAC inhibitors in vitro.Histone Deacetylase Inhibitors Delivery using Nanoparticles with Intrinsic Passive Tumor Targeting Properties for Tumor TherapyGenomic and Epigenomic Aberrations in Esophageal Squamous Cell Carcinoma and Implications for Patients.Response of esophageal cancer cells to epigenetic inhibitors is mediated via altered thioredoxin activity.DNA methyltransferase inhibitors: an updated patent review (2012-2015).HDACs and HDAC Inhibitors in Cancer Development and Therapy.The production of 3D tumor spheroids for cancer drug discovery.Subcellular localization of EGFR in esophageal carcinoma cell lines.A histone deacetylase inhibitor enhances expression of genes inhibiting Wnt pathway and augments activity of DNA demethylation reagent against nonsmall-cell lung cancer.Diallyl trisulfides, a natural histone deacetylase inhibitor, attenuate HIF-1α synthesis, and decreases breast cancer metastasis.Pharmacoepigenetics and pharmacoepigenomics of gastrointestinal cancers.The anti-tumor effects of dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A on inducing autophagy in esophageal squamous cell carcinoma.Downregulation of MiR-199b-5p Inducing Differentiation of Bone-Marrow Mesenchymal Stem Cells (BMSCs) Toward Cardiomyocyte-Like Cells via HSF1/HSP70 Pathway.Ex vivo drug sensitivity testing as a means for drug repurposing in esophageal adenocarcinomaConcept of histone deacetylases in cancer: Reflections on esophageal carcinogenesis and treatment
P2860
Q26745709-69A0A4AD-A597-4AE4-8739-AD28B353A963Q26751209-07AAA66A-489A-42B4-9E4B-54B0E372213DQ36853881-9E011CB3-FA39-4313-860A-3A4B6D253737Q36882942-CA65DC80-7988-437B-832F-39782FDE7015Q38649673-960A9741-24D1-4CFB-80CF-63D16E43AAACQ38809883-2119931E-6C1F-43D4-A8F5-97991D2947FCQ38885370-7A008152-032B-4EF2-83A4-5A68C3BEAD9DQ38947405-4085F835-F04B-45A3-80EF-A637E26B4A17Q39396046-063B98D8-90BA-4D15-8EB6-E8E846C9943EQ40784649-E63FC057-6562-450B-920C-8D6303FB987DQ48199426-18F33A3B-0E31-4923-BA50-79FE0C0A7705Q48336312-62D511A7-AB8F-408D-BC9E-1129C690E4C5Q50252299-9AE7663E-3FAF-40FA-8F93-D5D18AC27739Q52629243-B7479C1B-A4DA-4A36-BC0D-AB830F5F6ABEQ55105007-4FFC219B-5A8E-4511-A0C6-0E2070961E14Q57617318-16DFD821-64F4-46B8-81F7-9A0F91F4D563Q58699639-688FD197-D0A7-4621-BEB8-5B2F82D6C7F2
P2860
Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Selective inhibition of esopha ...... DAC inhibitors and Azacytidine
@en
type
label
Selective inhibition of esopha ...... DAC inhibitors and Azacytidine
@en
prefLabel
Selective inhibition of esopha ...... DAC inhibitors and Azacytidine
@en
P2093
P2860
P50
P1433
P1476
Selective inhibition of esopha ...... DAC inhibitors and Azacytidine
@en
P2093
Jenny Ostendorp
Jens Hoeppner
Martin Werner
Silke Lassmann
Sina Hembach
Sylvia Timme
Ulrich T Hopt
P2860
P304
P356
10.1080/15592294.2015.1039216
P577
2015-01-01T00:00:00Z